Phio Pharmaceuticals Establishes New At-the-Market Equity Program

Phio Pharmaceuticals ( (PHIO) ) has provided an announcement.

On April 8, 2026, Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. that allows the company to sell up to $6.36 million of its common stock from time to time under an existing shelf registration statement. Under the arrangement, H.C. Wainwright will act as sales agent on a commercially reasonable efforts basis, earning a 3% commission on gross proceeds, while Phio retains full discretion over whether, when, and how many shares to sell, giving it flexible access to equity capital but no assurance that any shares will ultimately be issued.

The most recent analyst rating on (PHIO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn) and limited valuation support (negative P/E, no dividend). Offsetting these are improved capitalization with zero debt, moderately improving near-term technical momentum, and positive pipeline/manufacturing corporate updates that strengthen the development outlook.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a biotechnology company whose primary activities center on developing and commercializing pharmaceutical products. The company accesses U.S. capital markets and uses equity offerings as a key tool to finance its operations and advance its pipeline of drug candidates.

Average Trading Volume: 3,864,043

Technical Sentiment Signal: Sell

Current Market Cap: $14.41M

See more data about PHIO stock on TipRanks’ Stock Analysis page.